Novavax raising $82M for vaccine R&D; Achaogen, FDA agree on SPA;

@FierceBiotech: The 2013 Fierce 15 biotech execs take a bow. Editor's corner | FierceBiotech's 2013 Fierce 15 | Follow @FierceBiotech

@JohnCFierce: Merck KGaA doubles down on Oncothyreon's failed cancer vaccine. Report | Follow @JohnCFierce

@DamianFierce: Apparently no one wanted to spend ~$3B on Clovis Oncology. Perhaps Big Pharma wants its biotechs to generate revenue. Story | Follow @DamianFierce

@EmilyMFierce: Stem cell reprogramming made easier by removing one protein. Popular yesterday from FierceBiotech Research | Follow @EmilyMFierce

> Rockville, MD-based Novavax ($NVAX) plans to raise $82 million from the sale of common stock. The new financing is intended to finance work on its pipeline of vaccines. Release

> South San Francisco-based Achaogen and the FDA have reached agreement on an SPA for a Phase III clinical trial of plazomicin in patients with serious multi-drug resistant gram-negative bacterial infections. Release

> San Diego-based La Jolla Pharmaceutical says it has raised $10 million in a new financing effort. Release

Medical Device News

@FierceMedDev: Biocept Laboratories becomes latest Dx outfit to explore IPO. ICYMI yesterday | Follow @FierceMedDev

@MarkHFierce: Medtronic won expanded indications for one of its key vascular stents. Release | Article | Follow @MarkHFierce

> Stryker inks $1.7B deal for Mako. News

> Tool to predict bad implant reactions shows potential. Item

> EnteroMedics slides after FDA squints at obesity device. Article

Pharma News

@FiercePharma: Lundbeck's refusal to sell pentobarbital to prisons hits Ohio's execution plans. More from Reuters | Follow @FiercePharma

@EricPFierce: FDA warning letter for Strides Arcolab Agila Speciaities plant arrives. Mylan not too concerned. Story from FiercePharmaManufacturing | Follow @EricPFierce

> Cost gatekeepers give final 'no' to Pfizer's targeted cancer drug Xalkori. Report

> Eli Lilly's diabetes strategy doesn't include big staff-up in sales. Article

Drug Delivery News

@MichaelGFierce: Laser-sensitive surface enables IV-drug identification for safer delivery. Story | Follow @MichaelGFierce

> Study: Artificial pancreas with inhaled insulin improves glucose control. More

> Alnylam heralds positive results for RNAi amyloidosis drug. Article

> Surefire collects $16.4M to expand cancer-drug catheter biz. Item

> Bind collects $70.5M IPO to support Accurin tech. Story

Diagnostics News

> Cognoptix Alzheimer's eye test generates robust trial results. Article

> Alzheimer's diagnosis may gain from PET imaging of tau proteins. Report

> Case Western, GSK find promise with MS diagnostic 'probe.' Story

> In vitro Dx to remain at top of med tech heap. More

> Cigna: Genetic counseling mandates will come for other Dx tests. Article

And Finally… A nail fungus drug has been proven effective at wiping out HIV in cell cultures. Story

Suggested Articles

A patient has died in the global study of AstraZeneca’s COVID-19 vaccine, Brazil’s health authority, Anvisa, announced on Wednesday.

MyoKardia wasn’t looking for a buyout when it started discussing potential partnerships with Bristol Myers Squibb last year.

The patient was hospitalized with febrile neutropenia in the weeks after receiving the drug and died 52 days post-treatment with the CAR-T therapy.